As of today (2026-06-30), the Forward Annual Dividend Yield of Novartis AG is 0.00%.
As of today (2026-06-30), the Trailing Annual Dividend Yield of Novartis AG is 0.00%.
XSWX:NOVNEE's Forward Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.12 * Ranked among companies with meaningful Forward Dividend Yield % only.
During the past 12 months, Novartis AG's average Dividends Per Share Growth Rate was 3.70% per year.
During the past 3 years, the average Dividends Per Share Growth Rate was 0.40% per year.
During the past 5 years, the average Dividends Per Share Growth Rate was 3.00% per year.
During the past 10 years, the average Dividends Per Share Growth Rate was 1.90% per year.
During the past 13 years, the highest 3-Year average Dividends Per Share Growth Rate of Novartis AG was 18.50% per year. The lowest was 0.00% per year. And the median was 5.30% per year.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
Novartis AG (XSWX:NOVNEE) Forward Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
Novartis AG Forward Dividend Yield % Related Terms
XSWX:NOVNEE vs LLY, JNJ, ABBV: Forward Dividend Yield % Comparison
For the Drug Manufacturers - General subindustry, Novartis AG's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Novartis AG Forward Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Novartis AG's Forward Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Novartis AG's Forward Dividend Yield % falls into.
What does a Forward Dividend Yield % of 0.00% mean?
Novartis AG (XSWX:NOVNEE) has a Forward Dividend Yield % of 0.00% as of Jun. 30, 2026. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Novartis AG and its competitors. According to the industry distribution chart, Novartis AG ranks #182 out of 505 companies in the Drug Manufacturers industry, placing it in the top 36%.
Is Novartis AG's Forward Dividend Yield % too high?
Novartis AG's current Forward Dividend Yield % is 0.00%. Based on the distribution chart, Novartis AG ranks #182 out of 505 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Novartis AG has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does Novartis AG's Forward Dividend Yield % compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Novartis AG ranks #182 out of 505 companies for Forward Dividend Yield %. This puts Novartis AG in the upper half of its industry. The industry median Forward Dividend Yield % is 2.12. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward Dividend Yield % for a Drug Manufacturers company?
The median Forward Dividend Yield % among Drug Manufacturers companies is 2.12, based on 505 companies in the industry. Companies in the top quartile (top 25%) have a Forward Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Forward Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward Dividend Yield % mean?
A high Forward Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Forward dividend yield is the ratio of company's expected dividends to the share price. View historical data on Novartis AG and its competitors. For the Drug Manufacturers industry, the median Forward Dividend Yield % is 2.12 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Novartis AG's current Forward Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Novartis AG stock overvalued right now?
Novartis AG (XSWX:NOVNEE) has a current Forward Dividend Yield % of 0.00%. The stock's GF Value™ is CHF97.39, compared to a current price of CHF119.30 — trading 22.5% above its estimated fair value. The current Forward Dividend Yield % is 0.00%. Novartis AG's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward Dividend Yield % calculated?
Forward Dividend Yield % is calculated from a company's financial statements. For Novartis AG (XSWX:NOVNEE), the current Forward Dividend Yield % is 0.00% as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Novartis AG (XSWX:NOVNEE) Overvalued in 2026?
Based on GuruFocus' analysis, Novartis AG stock appears to be overvalued.
The current stock price of CHF119.30 is trading 22.5% above its estimated GF Value™ of CHF97.39.
Key valuation signals for XSWX:NOVNEE:
Forward Dividend Yield %: 0.00%
GF Value™: CHF97.39 vs. price of CHF119.30 (22.5% above fair value)
No single metric tells the full story. See the XSWX:NOVNEE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Novartis develops and manufactures innovative drugs. Key areas of drug development are oncology, immunology, neuroscience, respiratory, and cardiovascular, renal, and metabolic. It also has an established medicines business, which includes off-patent franchises. The company sells its products globally, with the United States constituting close to one-third of total revenue.
83GF Score
Get the complete analysis for XSWX:NOVNEE
Forward Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:NOVNEE has been successfully added to your 